Evoke Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Evoke Pharma has a total shareholder equity of $4.4M and total debt of $5.0M, which brings its debt-to-equity ratio to 114.3%. Its total assets and total liabilities are $16.1M and $11.7M respectively.
Key information
114.30%
Debt to equity ratio
US$5.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$12.06m |
| Equity | US$4.37m |
| Total liabilities | US$11.69m |
| Total assets | US$16.06m |
Recent financial health updates
Recent updates
Investors Still Aren't Entirely Convinced By Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Despite 31% Price Jump
Aug 19
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jul 30Evoke Pharma, Inc. (NASDAQ:EVOK) Might Not Be As Mispriced As It Looks After Plunging 27%
Jun 22Market Cool On Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Pushing Shares 29% Lower
Mar 16Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Financial Position Analysis
Short Term Liabilities: EVOK's short term assets ($15.9M) exceed its short term liabilities ($11.6M).
Long Term Liabilities: EVOK's short term assets ($15.9M) exceed its long term liabilities ($65.0K).
Debt to Equity History and Analysis
Debt Level: EVOK has more cash than its total debt.
Reducing Debt: EVOK had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVOK has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: EVOK has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 5% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/28 18:34 |
| End of Day Share Price | 2025/09/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evoke Pharma, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Difei Yang | Brean Capital |
| David Buck | B. Riley Securities, Inc. |